Three years ago, I had one of the worst surfing injuries of my life…
After I wiped out, my board came straight down into my back.
The accident resulted in four broken ribs and a collapsed lung.
But it also gave me another personal reason to support the emerging plant-based medicines industry.
See, despite recent scientific research showing the efficacy of psychedelic medicines… when most people hear about them they immediately start thinking about party drugs.
Things like psilocybin (“magic mushrooms”), LSD (“acid”), or MDMA (“ecstasy”).
Yet, the irony is that some of these oft-demonized “drugs” not only have very legitimate medical purposes… they may actually help solve America’s current opioid epidemic.
And as I’ll show you below, they might also make early investors a fortune along the way.
A Better Way to Approach Pain Management
I have a pretty high pain tolerance.
In fact, right after my surfboard hit me in the back and caused all that internal damage, I tried to paddle back out and catch another wave.
But after that attempt failed…
And after a couple of hours trying to pretend everything was fine…
I ended up in the hospital with a tube inserted on my side to help drain all the blood out of my chest cavity… and to allow my lung to reinflate.
Between the initial injuries and the additional pain caused by the tube, I was in for a couple of long nights.
To help ease the pain, a nurse came in and offered me the standard treatment: Oxycontin (oxycodone hydrochloride).
I quickly declined.
After all, oxycontin and other prescription opioids are known to be highly addictive.
We’ve all read stories of people who started out using these substances for legitimate pain management and ended up hooked well beyond the duration of the original problem.
The National Institute for Drug Abuse says almost half of all opioid deaths in the U.S. now involve prescription opioids.
Suffice it to say, I was not interested in going down that path…
So the nurse suggested another option – ketamine.
Most people know this psychedelic compound as the club drug “special k.” And there’s no doubt that some people misuse or abuse it.
At higher doses, it can change your perception of sights and sounds and create hallucinations.
However, when administered correctly, ketamine is a very effective medication for pain management.
That’s because, at lower doses, it merely creates a general sense of detachment from your current physical condition.
In my particular case, a relatively small oral dose helped me relax and minimized my focus on the tube sticking out of my side.
I never felt out of it. I didn’t see things that weren’t there. I was able to have normal conversations with visitors. I just felt calm.
Better yet, after the initial day and a half of ketamine, I switched over to regular Tylenol and never looked back.
Indeed, ketamine has far less risk of addiction than opiates.
And researchers are now exploring other uses far beyond short-term pain management…
Ketamine has been used as a sedative for surgery since the Vietnam War.
But in 2006, the medical community woke up to a new use for ketamine: Treating mental health disorders.
A piece published in the Pain Medicine Journal revealed the astounding and unexpected discovery.
Then study after study came back showing ketamine’s powerful effect…
For instance, Dr. Thomas Insel, the director of the National Institute of Mental Health has said, “Recent data suggest that ketamine, given intravenously, might be the most important breakthrough in antidepressant treatment in decades.”
And in 2019, the FDA gave Johnson & Johnson (J&J) a “breakthrough” treatment designation for Spravato – a ketamine-based antidepressant.
Spravato boosts the activity of certain receptors in the brain to cope more effectively with stress.
Since it’s a nasal spray, Spravato is absorbed through the mucous membranes in your nose and works almost immediately… while traditional antidepressants can take weeks to show any signs of improvement – if at all.
Spravato is unlike any medication doctors have prescribed in 50 years. And it could drastically improve the lives of millions of people.
And that’s still only the beginning…
According to The Psychiatric Times, psychedelic substances are treating all types of mental health disorders like substance abuse and addiction.
Based on our research, these illnesses cost society nearly $3 trillion per year in health expenses and lost productivity.
Psychedelic medicines aim to solve these disorders.
So, it may very well turn out that something like ketamine isn’t just a better pain treatment than oxycontin… but also a benefit to people who are currently hooked on it.
In short, the science is starting to point to many possible medicinal uses of compounds that were once demonized as fringe recreational drugs… the continuation of a trend that began with cannabis over the last decade.
That’s excellent news for humanity.
And it could also be great news for anyone who has the foresight to start investing in the small companies spearheading this new revolution in medicine.
How to Play This Trend
If you’re looking for broad exposure to the psychedelics medicine trend, consider Johnson & Johnson.
Of course, J&J is already a giant pharmaceutical company.
And while Spravato’s success could help J&J do well, it won’t deliver life-changing gains to J&J’s investors.
The drug’s target market is only a fraction of the bigger picture. Plus, J&J’s days of massive growth are far behind it.
That’s why Daily editor Teeka Tiwari searched for life-changing asymmetric plays in this emerging field. And he’s found five small, early-stage companies to play this trillion-dollar trend…
The joint market they’re targeting comprises 800 million people… and each has the ability to return 100 years’ worth of stock market gains – or more – in just 18 months.
Teeka put all the details together in this special presentation. He’s even partnered up with one of the leading experts in psychedelic therapeutics… “Psychedelics Concierge to the Stars,” Mike “Zappy” Zapolin.
Teeka and Zappy think this trend will be so massive, it could possibly be Teeka’s third trillion-dollar trade.
Teeka’s first trillion-dollar trade was in 2003 when he identified Apple, the world’s first trillion-dollar company. His second trillion-dollar trade happened when he found cryptocurrencies in 2016 – today worth over $1 trillion.
And during his presentation, Teeka and Zappy explained why medicinal psychedelics like ketamine and psilocybin will be his third.
Don’t get left behind. Check out Teeka’s presentation and learn why psychedelic therapeutics could become one of the most significant medical breakthroughs of our lifetime… and make early investors a fortune.
Analyst, Palm Beach Daily